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OBJECTIVES To evaluate a quantitative model of restenosis in patients with vein graft disease undergoing
percutaneous transluminal coronary angioplasty (PTCA) or directional coronary atherectomy
(DCA).
BACKGROUND A quantitative relationship between acute gain and late loss has been developed to describe
the late changes in lumen dimension after native vessel coronary intervention. This same
relationship may also be seen after treatment of saphenous vein graft disease.
METHODS Patients with native coronary artery stenoses (CAVEAT-I) or saphenous vein graft lesions
(CAVEAT-II) were randomized to either DCA or PTCA, and data from these trials were
analyzed retrospectively. Angiographic results of the target lesions were reviewed, and each
lesion was assessed for vessel caliber and reference diameter, absolute minimal lumen
diameter, percent diameter stenosis, percent stenosis of the cross-sectional area, acute gain
and late loss. Linear regression models were used to determine late loss and to detect
differences in angiographic outcomes.
RESULTS Vein grafts had significantly larger reference vessel diameters than native coronary arteries;
they also had significantly more acute gain and more late loss. Directional coronary
atherectomy was associated with a larger acute gain in both studies. Patients undergoing
DCA also experienced greater late loss although the effect was statistically significant only in
the CAVEAT-I study. After adjusting for the acute gain, the treatment effect on late loss
became nonsignificant in both studies.
CONCLUSIONS In patients undergoing DCA or PTCA of saphenous vein graft narrowings, the relationship
between late loss and acute gain is also demonstrated, similar to the device-independent
relationships seen in native coronary lesions. In CAVEAT-II, larger degrees of acute gain
were also associated with higher degrees of late lumen loss. (J Am Coll Cardiol 2000;35:
619–23) © 2000 by the American College of Cardiology
Restenosis following percutaneous coronary revasculariza-
tion has been studied extensively using quantitative angio-
graphic methods, yielding insights into the dynamic
changes occurring early and late after intervention. In
addition, there is substantial interest in the relationship
between initial gain and late loss.
Differences in restenosis rates among interventional de-
vices have been related to the immediate angiographic
outcome. Long-term angiographic outcomes were evaluated
by Kuntz et al. (1). These investigators developed a quan-
titative model of procedural angiographic predictors of late
loss (defined as postprocedural minimal lumen diameter [in
mm]–minimal lumen diameter at six months [in mm]).
Their modeling process also evaluated differences in late loss
using different devices after adjusting for these procedural
factors. However, their work was in native coronary artery
lesions and not in saphenous vein graft disease.
This study first sought to validate the results found by
Kuntz et al. (1) in patients undergoing native vessel coro-
nary intervention in the Coronary Angioplasty Versus
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Excisional Atherectomy Trial-I (CAVEAT-I) (2,3). Then
a similar model was developed for patients undergoing
saphenous vein graft intervention using directional atherec-
tomy or balloon angioplasty in the randomized Coronary
Angioplasty Versus Excisional Atherectomy Trial-II
(CAVEAT-II).
METHODS
Study patients and angiographic analysis. CAVEAT-I
and CAVEAT-II randomized patients with de novo native
coronary arterial stenosis (CAVEAT-I, 1,012 patients) or
de novo saphenous vein graft lesions (CAVEAT-II, 305
patients) to either directional coronary atherectomy (DCA)
or percutaneous transluminal coronary angioplasty (PTCA).
A validated edge-detection algorithm was used to analyze
paired acute and six-month follow-up angiograms at the
core angiographic laboratory at the Cleveland Clinic Foun-
dation (4). The most severe hemiaxial end-diastolic frame
selected from two orthogonal views without vessel shorten-
ing was used for analysis. Each lesion was assessed for
reference diameter, absolute minimal lumen diameter
(MLD), percent diameter stenosis (DS%), acute gain
(MLD post–MLD pre), late loss (MLD immediately post–
MLD at follow-up) and late loss index (late loss/initial gain)
(1).
Statistical analysis. Continuous variables are summarized
as medians (25th, 75th percentiles). Frequencies are dis-
played as counts and percentages. We employed general
linear models (GLM) using SAS statistical software to
detect differences in angiographic factors for PTCA versus
DCA and native arteries versus grafts.
We analyzed CAVEAT-I and CAVEAT-II patients
separately. For each study, univariable regression models
tested the differences in the distributions of angiographic
factors for the two devices. All of the angiographic factors
were first evaluated for normality and were determined to
have met this assumption.
Late loss was evaluated further within each of the two
CAVEAT studies. First, models with all two-way combi-
nations of acute gain, pre-MLD and post-MLD deter-
mined which combination of two of these three factors best
predicted late loss. Next, stepwise variable selection, using as
potential covariates the primary two MLD measures—pre-
and post-percent stenosis and pre- and post-diameter ste-
nosis—gave a set of angiographic factors that were jointly
related to the six-month outcome of interest. Variables were
retained if they were significant multivariable predictors at
alpha 5 0.05.
The key angiographic factor(s) found in the stepwise
process as well as the randomized treatment were included
into a regression model of late loss. This tested the treat-
ment effect after adjusting for the pre- and post-procedural
results. Then the interaction of treatment with the angio-
graphic factor(s) was tested. These two sets of analyses
allowed us to see if the treatment effect remained after
taking angiographic results into account and whether the
effect of pre- or post-procedural results on six-month
outcome was similar for the two procedures.
Of special interest was the relationship between early gain
and late loss. Therefore, the effect of early gain on late loss
was also tested in a similar fashion, regardless of the
stepwise results. Three sets of predictors were modeled:
early gain, early gain plus treatment and early gain, treat-
ment and the interaction of the two.
RESULTS
The baseline characteristics of the patients in the two trials
have been previously described. Within each trial, patients
randomized to either PTCA or DCA had similar baseline
clinical characteristics (Table 1). Patients in CAVEAT-II,
however, were older, more often male, had more comor-
bidities and had evidence of more serious coronary disease
than patients in CAVEAT-I. Angiographic follow-up was
available in 700 patients (87% of successful procedures) in
CAVEAT-I and in 197 patients (82% of successful proce-
dures) in CAVEAT-II.
Early gain. The baseline quantitative coronary angio-
graphic findings can be seen in Table 2. Vein grafts had
significantly larger reference vessel diameters (p , 0.001)
and significantly more early gain than native coronary
arteries (p , 0.001). There was little difference in baseline
diameter stenosis between the two lesion types: 72.1%
versus 72.6%. Within each study, DCA was associated with
a significantly larger early gain than PTCA (p , 0.001 for
each).
Late loss. Patients with disease in their native coronary
arteries who were randomized to DCA had significantly
greater late loss than those randomized to PTCA (p ,
0.001). The two groups were not statistically different in
both follow-up minimal lumen diameter (p 5 0.205) and
diameter stenosis (p 5 0.074). Thus, the increased late loss
in the DCA group appeared to be due to increased initial
early gain. Effect of treatment type on late loss became
nonsignificant (p 5 0.108) when adjusted for early gain. It
appears that the trend is for most of the treatment difference
Abbreviations and Acronyms
CAVEAT-I 5 Coronary Angioplasty Versus Excisional
Atherectomy Trial-I
CAVEAT-II 5 Coronary Angioplasty Versus Excisional
Atherectomy Trial-II
DCA 5 directional coronary atherectomy
DS% 5 percent diameter stenosis
GLM 5 general linear models
MLD 5 absolute minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
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in late loss to be in patients with small early gains (Fig. 1).
However, the test for an interaction of early gain and
treatment was not significant (p 5 0.403).
In patients with vein grafts, the effect of treatment on late
loss was not significantly different (p 5 0.556), and the
absolute difference in late loss for the two treatment arms
did not differ significantly from the absolute difference seen
in CAVEAT-I. As with CAVEAT-I, the two treatment
arms in CAVEAT-II had similar minimal lumen diameter
(p 5 0.282) and percent stenosis at follow-up (p 5 0.168).
After adjusting for acute gain, the treatment type remained
nonsignificant (p 5 0.487). Figure 2 shows the relationship
Table 1. Baseline Clinical Characteristics
CAVEAT-I CAVEAT-II
DCA PTCA p Value DCA PTCA p Value
Characteristic (N 5 512) (N 5 500) (N 5 149) (N 5 156)
Age (yr)*† 59 (51, 67) 59 (52, 67) 0.822 66 (58, 71) 65 (58, 71) 0.936
Male gender (%)† 75 70 0.087 83 85 0.626
Weight (kg)* 82 (73, 92) 82 (72, 93) 0.532 82 (74, 90) 81 (72, 92) 0.788
Height (cm)* 173 (165, 178) 173 (165, 178) 0.947 170 (167, 177) 173 (167, 178) 0.226
Diabetes (%)† 19 19 0.793 36 33 0.514
Current smoker (%)† 29 28 0.748 22 14 0.063
Hypertension (%)† 52 54 0.557 64 60 0.529
Hypercholesterolemia (%)† 46 44 0.560 60 59 0.984
History of MI (%)† 44 41 0.345 73 63 0.053
Unstable angina (%)† 66 71 0.133 89 88 0.824
Ejection fraction*† 59 (50, 65) 60 (50, 65) 0.280 52 (45, 60) 50 (44, 60) 0.444
*Medians 25th, 75th percentiles; †For comparison of CAVEAT-I vs. CAVEAT-II, p value , 0.05.
p values for categorical values are calculated using a Log-likelihood chi-square. p values for continuous variables are calculated using a Wilcoxon signed-rank test.
CAVEAT-I, II 5 Coronary Angioplasty Versus Excisional Atherectomy Trial-I, -II; DCA 5 directional coronary atherectomy; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty.
Table 2. Angiographic Indexes at Baseline and Late (6 Months) After Intervention
CAVEAT-I CAVEAT-II
DCA
(N 5 512)
PTCA
(N 5 500) p Value
DCA
(N 5 149)
PTCA
(N 5 156) p Value
Procedural results
Successes 425 (88.9%) 376 (79.7%) , 0.001 124 (89.2%) 117 (79.0%) 0.018
Failures 53 (11.1%) 96 (20.3%) 15 (10.8%) 31 (21.0%)
Successful procedures
With angio F/U
372 (87.5%) 328 (87.2%) 0.900 103 (83.1%) 94 (80.3%) 0.585
Patients missing
Procedural results
34 (6.6%) 28 (5.6%) 10 (6.7%) 8 (5.1%)
MLD (mm)
Pre† 0.81 (0.62, 1.05) 0.79 (0.60, 1.07) 0.402 0.92 (0.70, 1.23) 1.03 (0.76, 1.29) 0.108
Post† 1.89 (1.56, 2.18) 1.66 (1.42, 1.98) , 0.001 2.43 (1.99, 2.95) 2.22 (1.82, 2.62) 0.006
F/U† 1.35 (0.90, 1.78) 1.23 (0.89, 1.65) 0.076 1.78 (1.20, 2.27) 1.61 (0.92, 2.18) 0.145
DS (%)
Pre 71.6 (63.3, 77.6) 72.8 (62.8, 78.9) 0.169 73.7 (65.6, 80.4) 71.7 (63.8, 79.2) 0.103
Post† 33.4 (25.3, 41.8) 40.7 (33.4, 48.6) , 0.001 31.5 (23.5, 39.4) 37.6 (28.6, 45.6) , 0.001
Follow-up 52.1 (37.2, 65.5) 54.8 (41.8, 67.1) 0.036 47.3 (37.2, 67.9) 52.5 (40.2, 74.0) 0.100
Reference Vessel (mm)
Pre† 2.77 (2.40, 3,11) 2.75 (2.42, 3.12) 0.998 3.45 (3.04, 3.82) 3.46 (2.97, 3.98) 0.866
Post† 2.74 (2.42, 3.13) 2.77 (2.40, 3.16) 0.734 3.44 (2.96, 3.83) 3.38 (2.99, 3.94) 0.942
Follow-up† 2.71 (2.36, 3.06) 2.74 (2.34, 3.07) 0.648 3.42 (2.96, 3.88) 3.42 (2.98, 3.93) 0.895
Acute gain (mm)† 1.05 (0.70, 1.30) 0.86 (0.54, 1.17) , 0.001 1.45 (0.99, 1.92) 1.12 (0.78, 1.58) , 0.001
Late Loss (mm)† 0.54 (0.15, 0.91) 0.41 (0.05, 0.78) 0.002 0.62 (0.24, 1.40) 0.53 (0.10, 1.16) 0.565
Loss Index 0.53 (0.15, 0.92) 0.50 (0.08, 0.91) 0.239 0.40 (0.16, 0.84) 0.53 (0.10, 1.04) 0.567
Angio F/U 5 angiography follow-up; CAVEAT-I, -II 5 Coronary Angioplasty Versus Excisional Atherectomy Trial-I, -II; DCA 5 directional coronary atherectomy; DS 5
percent diameter stenosis; MLD 5 minimal lumen diameter; PTCA 5 percutaneous transluminal coronary angioplasty.
†For comparison of CAVEAT-I vs. CAVEAT-II, p value , 0.05.
p values for categorical values are calculated using a Log-likelihood chi-square. p values for continuous variables are calculated using a Wilcoxon signed-rank test.
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between early gain and late loss for the two treatment arms.
The test for an interaction between these two factors was
not significant (p 5 0.312).
Multivariable analysis of late loss. Multivariable analysis
was performed to assess relationships between geometric
determinants and late loss in vein grafts compared with
native coronary lesions. In CAVEAT-I, when late loss was
modeled with pre- and post-angiographic variables, premi-
nimal luminal diameter. postminimal luminal diameter and
postpercent stenosis were all found to be significant inde-
pendent predictors of late loss (p 5 0.001 for each after
adjusting for the other two factors). After adjusting for these
three angiographic variables, the effect of treatment type
(i.e., PTCA vs. DCA) on late loss was no longer significant
(p 5 0.802). There was also no significant interaction of
device type with these three procedural factors. In contrast,
in CAVEAT-II only pre- and post-minimal luminal diam-
eters were significant independent predictors of late loss
(p 5 0.003 and ,0.001, respectively); postprocedural ste-
nosis did not remain significant after adjusting for pre- and
post-minimal luminal diameters. In addition, the treatment
type in CAVEAT-II was nonsignificant both unadjusted in
the univariable model (p 5 0.556) (unlike CAVEAT-I) and
after adjusting for the pre- and post-minimal luminal
diameter in the multivariable model (p 5 0.494).
DISCUSSION
Restenosis after percutaneous revascularization in saphe-
nous vein grafts has been less well studied than restenosis in
native coronary arteries, due, in part, to fewer well-
controlled trials of vein graft revascularization procedures
and, in part, to the lack of a laboratory model of vein graft
restenosis. Until now, it has been unknown whether similar
principles of restenosis in native coronary arteries apply to
vein grafts.
Vein grafts as arterial conduits. There are notable differ-
ences in the anatomical/histological properties of coronary
arteries and saphenous veins (Table 3), particularly when the
vein is used as an arterial conduit (5,6). This results from
several factors: increased intraluminal pressure, graft wall
ischemia, thrombosis or fibrin deposition from either isch-
emia or trauma or both, with secondary repair of the
damaged endothelium and intima. As a consequence, his-
tological examination of vein grafts in place from two to 72
months reveals a marked increase in fibrous tissue in all
three layers (5). In older grafts, atherosclerosis becomes
more of a problem.
Vein graft histology and response to angioplasty vary in
relation to the age of the graft (7). Graft compromise within
the first month of insertion is usually due to thrombosis
secondary to technical operative factors. The histology of
stenoses of vein grafts treated within 1 year of insertion is
characterized by intimal thickening secondary to cellular or
acellular fibrocollagenous tissue and thick fibrotic medial
and adventitial layers. The dilating mechanism has, there-
Figure 1. Predicted late loss by early gain in CAVEAT-I.
Figure 2. Predicted late loss by early gain in CAVEAT-II.
Table 3. Differences Between Native Coronary Arteries and
Saphenous Vein Grafts
Layers
Native Coronary
Arteries
Saphenous Vein
Grafts
Intima IEL present No IEL present
Media Thicker Thin
Adventitia EEL present No EEL present
EEL 5 external elastic lamina; IEL 5 internal elastic lamina.
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fore, been postulated to be graft stretching rather than
intimal compression. Graft “restenosis” represents restitu-
tion of tone of the overstretched segment. For grafts older
than one year, the stenoses are usually composed of athero-
sclerotic plaque associated with intimal fibrous thickening,
which is morphologically similar to native coronary arteries.
The mechanism of dilation in these older grafts is similar to
coronary artery PTCA, i.e., plaque splitting, cracking or
breaking with or without localized intimal/medial dissec-
tion. In this study, most of the grafts were considerably
older than one year (median graft age over nine years).
Theories of restenosis after percutaneous revasculariza-
tion. Theories of restenosis following percutaneous revas-
cularization center on two major issues: neointimal prolif-
eration and geometric remodeling (8). Several mechanisms
have been postulated to explain remodeling after coronary
angioplasty (9) including: 1) fibrosis of the vessel wall,
especially of the adventitia in response to deep wall injury, 2)
apoptosis, 3) changes in the extracellular matrix composi-
tion and structure, and 4) responses to shear stress-induced
changes in vasomotor tone. The media is not likely to be
responsible for remodeling. Analysis of severely narrowed
coronary arteries has repeatedly shown depletion of medial
components; therefore, meaningful reduction in medial
thickness accounting for a decrease in the cross-sectional
area would be unlikely (10). Interestingly, it is the thickness
of the media that most distinguishes veins from arteries.
Thus, if the media indeed plays a minor role in restenosis,
arteries and veins would be expected to respond similarly to
injury despite differences in medial thickness.
A quantitative model of restenosis applied to vein grafts.
A quantitative model of restenosis (1) has been developed
and applied to native coronary arteries. With this model,
apparent differences in restenosis rates among different
interventional devices are related to the immediate outcome
achieved rather than the device used. Our study first sought
to validate these results in native coronary arteries and then
tested this model in patients undergoing saphenous vein
graft intervention. The most notable finding is that, despite
histological/anatomical differences and differences in vessel
caliber between native coronary arteries and saphenous vein
grafts, there were no differences in late loss using the two
devices, similar to findings in the native coronary vessels.
Because of a larger reference vessel size, both acute gain and
late loss were greater in vein grafts compared with native
vessels.
Study limitations. This is a retrospective study of a sub-
group of patients of a larger study comparing DCA with
PTCA. Only lesions amenable to both interventions were
studied, which may have selected a group of patients with
similar plaque/vessel characteristics. A histological compar-
ison of the atherectomy samples may have provided addi-
tional insight into both differences between and similarities
in vein grafts and native vessels.
Conclusions. Our results closely mirrored those reported
in prior quantitative angiographic studies. In the largest of
these studies, univariable analysis showed that device type
influenced late angiographic outcome, although correction
of the multivariable model by the postprocedure minimal
luminal diameter negated this effect (1). Therefore the final
multivariable linear and logistic models demonstrated that
the outcomes were determined independently by the imme-
diate results alone and not by the device used. These
findings were observed in both the CAVEAT-I and
CAVEAT-II studies, suggesting that restenosis is primarily
determined by the immediate result alone. This finding
should be restudied prospectively using an appropriately-
sized patient population.
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